reports
Intercontinental Exchange Inc: 1 director
A director at Intercontinental Exchange Inc sold after exercising options/sold 168,388 shares at 137.212USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compa...
- MarketLine Department
London Stock Exchange Group Plc - Mergers & Acquisitions (M&A), Partne...
Summary Marketline's London Stock Exchange Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by London Stock Exchange Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships...
Moody's Assigns A3 rating to Intercontinental Exchange's proposed $1 b...
Moody's Investors Service (Moody's) has assigned an A3 rating to Intercontinental Exchange, Inc.'s (ICE, A3 stable) proposed $1 billion senior unsecured notes due 2028. ICE's rating outlook remains unchanged at stable. As part of its September 2023 Black Knight, Inc. (Ba2, ratings under review) acq...
Moody's affirms Intercontinental Exchange's ratings (A3 senior unsecur...
Moody's Investors Service (Moody's) has affirmed Intercontinental Exchange, Inc.'s (ICE) A3 senior unsecured debt rating and its Prime-2 commercial paper rating. ICE's outlook remains stable. The rating action followed ICE's 25 August 2023 announcement[1] that it expects to close its acquisition o...
- MarketLine Department
London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance...
Summary London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights London Stock Exchange Group plc (LSEG) operates a stock exchange and offers diversified global market infrastructure solutions. It manages international equity, bonds, and capi...
Moody's affirms Intercontinental Exchange's A3 rating following FTC's ...
Moody's Investors Service (Moody's) today affirmed Intercontinental Exchange, Inc.'s (ICE) A3 senior unsecured debt rating and its Prime-2 commercial paper rating. ICE's outlook remains stable. The rating action followed the Federal Trade Commission's (FTC) 9 March 2023 announcement[1] that it is ...
Moody's affirms ICE's A3 ratings following announced agreement to acqu...
Moody's Investors Service (Moody's) today affirmed Intercontinental Exchange, Inc.'s (ICE) A3 senior unsecured debt rating and its Prime-2 commercial paper rating. ICE's outlook remains stable. The rating action followed ICE's 4 May announcement[1] that it has agreed to acquire Black Knight, Inc. a...
- Valens Research
Valens Equity Insights and Inflections - 2022 03 15
Ichor Holdings, Ltd. (ICHR) is the dominant player in a critical memory chip subindustry, and it is improving profitability coming out of a difficult two-year period for the industry. Uniform Accounting highlights that the market is missing the company's improving fundamentals, creating an opportunity for equity upside. Ichor is the biggest and highest quality fluid and gas delivery system manufacturer, a key supplier to the growing memory chip market. Difficult supply dynamics in the memory ma...
ANET ARISTA NETWORKS INC.
TMO THERMO FISHER SCIENTIFIC INC.
NVDA NVIDIA CORPORATION
LDOS LEIDOS HOLDINGS INC.
ICE INTERCONTINENTAL EXCHANGE INC.
GILD GILEAD SCIENCES INC.
CPRT COPART INC.
CME CME GROUP INC. CLASS A
TTD TRADE DESK INC. CLASS A
ICHR ICHOR HOLDINGS LTD.
- Valens Research
ICE - Embedded Expectations Analysis - 2022 03 11
Intercontinental Exchange (ICE) currently trades above corporate and recent averages relative to Uniform earnings, with a 25.3x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to compress to 51%, accompanied by 7% Uniform asset growth. Similarly, analysts expect Uniform ROA to decline to 52% in 2023, accompanied by 5% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $128, representing approximately...
- Valens Research
Valens Equity Insights and Inflections - 2022 02 08
CVS Health Corporation (CVS) is in the midst of a transition from pharmacy business to a massively profitable medical data and technology company. Uniform Accounting confirms that the transition is underway and that the market isn't pricing this in. Considering management's strong execution and alignment to continue executing, equity upside continues to be warranted With CVS's acquisition of Aetna, the company is pivoting its business to become a complete medical data and technology company, s...
PG PROCTER & GAMBLE COMPANY
MAR MARRIOTT INTERNATIONAL INC. CLASS A
ISRG INTUITIVE SURGICAL INC.
ICE INTERCONTINENTAL EXCHANGE INC.
FDX FEDEX CORPORATION
DUK DUKE ENERGY CORPORATION
DE DEERE & COMPANY
CVS CVS HEALTH CORPORATION
CAT CATERPILLAR INC.
MRVI MARAVAI LIFESCIENCES HOLDINGS
- Valens Research
ICE - Embedded Expectations Analysis - 2022 02 02
Intercontinental Exchange (ICE) currently trades above corporate and recent historical averages relative to Uniform earnings, with a 28.0x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to expand to 69%, accompanied by 5% Uniform asset growth. However, analysts expect Uniform ROA to decline to 52% in 2022, accompanied by 10% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $114, representing appro...
- Valens Research
Valens Equity Insights and Inflections - 2021 11 02
Merck's (MRK) flagship Keytruda drug has substantially higher economic moats than the market realizes, and it has the potential to expand its profitability further. Uniform Accounting highlights that the market is missing Keytruda's economic potential, indicating equity upside. In addition to its solid portfolio of cash cow drugs, Merck's flagship biologic drug, Keytruda, has accelerated the company's earnings potential, helping grow Uniform ROA from 11% to 15%, and a forecast rise to 18%. As i...
NOW SERVICENOW INC.
SO SOUTHERN COMPANY
POST POST HOLDINGS INC.
ORCL ORACLE CORPORATION
MRK MERCK & CO. INC.
LEN LENNAR CORPORATION CLASS A
ICE INTERCONTINENTAL EXCHANGE INC.
GILD GILEAD SCIENCES INC.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
DE DEERE & COMPANY
D DOMINION ENERGY INC
CRM SALESFORCE.COM INC.
CME CME GROUP INC. CLASS A
CL COLGATE-PALMOLIVE COMPANY
BDX BECTON DICKINSON AND COMPANY
APD AIR PRODUCTS AND CHEMICALS INC.
ADSK AUTODESK INC.
ZG ZILLOW GROUP INC. CLASS A
DASH DOORDASH
SNOW SNOWFLAKE INC. CLASS A
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.